Latest Mass drug administration Stories
A team of scientists from The Scripps Research Institute, the Genomics Institute of the Novartis Research Foundation (GNF), and the U. S. Naval Research Detachment in Peru has completed a study that could improve the efficacy of diagnosis and treatment strategies for drug-resistant malaria.
Current tools for combating malaria, such as artemisinin-combination therapy and increasing coverage of long-lasting insecticide bednets can result in major reductions in Plasmodium falciparum malaria transmission and the associated disease burden in Africa.
Researchers are a step closer to developing new antimalarial drugs after discovering the normal function of a set of proteins related to the malaria parasite protein, which causes resistance to the front-line drug chloroquine.
ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk.
Current combination malaria therapies recommended by the World Health Organization (WHO) provide adequate treatment for mild malaria, according to a Cochrane Systematic Review of the evidence.
The first evidence of resistance to the world's most effective drug for treating malaria has been found by international scientists.
A disease once thought to be somewhat under control with the use of prescription drugs is emerging at the Thai-Cambodian border as drug resistant.
The afflictions of impoverished Cambodia can be seen in the nationâ€™s western corner: girls for hire standing outside restaurants, uneven dirt roads dotted with signs that warn â€œDanger Mines!â€
Text of report by Nairobi-based online news service of UN regional information network IRIN on 19 September Kampala, 19 September 2008: The Ugandan government is to subsidize the most effective form of malaria treatment sold in the private sector.
WASHINGTON (Reuters) - An allergy drug pulled off the market in 1999 could work to treat malaria, U.S. researchers reported on Sunday.